BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 12810619)

  • 1. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
    Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
    J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor stem cell research - basis and challenge for diagnosis and therapy].
    Karlic H; Herrmann H; Schulenburg A; Grunt TW; Laffer S; Mirkina I; Hubmann R; Shehata M; Marian B; Selzer E; Pfeilstöcker M; Pittermann E; Jäger U; Pehamberger H; Zielinski C; Valent P
    Wien Klin Wochenschr; 2010 Jul; 122(13-14):423-36. PubMed ID: 20645015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
    Yaccoby S
    Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of clonogenic multiple myeloma cells.
    Matsui W; Huff CA; Wang Q; Malehorn MT; Barber J; Tanhehco Y; Smith BD; Civin CI; Jones RJ
    Blood; 2004 Mar; 103(6):2332-6. PubMed ID: 14630803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
    Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
    Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
    Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
    Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
    Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.
    Asosingh K; Günthert U; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
    Cancer Res; 2001 Apr; 61(7):2862-5. PubMed ID: 11306459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
    Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
    Asosingh K
    Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic neutrophilic leukemia].
    Gastearena J; Orúe MT; Uriz MJ; Pérez Equiza E; Calavia J; Gorosquieta A
    Sangre (Barc); 1995 Dec; 40(6):499-503. PubMed ID: 8850234
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.